

# WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS

Forty-fourth report



World Health  
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective — the attainment by all people of the highest possible level of health.

---

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs CHF/US\$ 188.00 (CHF/US\$ 143.00 in developing countries). For further information, please contact WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int); order online at <http://www.who.int/bookorders>).

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization*

**WHO Technical Report Series**

**957**

---

# **WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS**

---

Forty-fourth report



**World Health  
Organization**

---

WHO Library Cataloguing-in-Publication Data:

Forty-fourth report of the WHO Expert Committee on specifications for pharmaceutical preparations.

(WHO technical report series; no. 957)

1. Pharmaceutical preparations — standards. 2. Technology, Pharmaceuticals — standards. 3. Drug industry — legislation. 4. Quality control. I. World Health Organization. II. Series.

ISBN 978 92 4 120957 1  
ISSN 0512-3054

(NLM classification: QV 771)

**© World Health Organization 2010**

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications—whether for sale or for noncommercial distribution—should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

**Typeset in Switzerland  
Printed in Switzerland**

# Contents

1. Introduction	1
2. General policy	3
2.1 International collaboration	3
2.1.1 International organizations, agencies and nongovernmental organizations	3
European Directorate for the Quality of Medicines and HealthCare	3
European Medicines Agency	4
The Global Fund to Fight AIDS, Tuberculosis and Malaria	4
Groupement International de la Répartition Pharmaceutique — European Association of Pharmaceutical Full-line Wholesalers	4
International Federation of Pharmaceutical Manufacturers and Associations	5
International Generic Pharmaceutical Alliance	5
International Pharmaceutical Federation	6
United Nations Children's Fund	6
2.1.2 Pharmacopoeial Discussion Group	7
2.1.3 International Conference on Harmonisation	8
2.1.4 International Conference of Drug Regulatory Authorities	8
2.2 Cross-cutting issues in pharmaceuticals — quality assurance issues	9
2.2.1 Herbal medicines	9
2.2.2 Biologicals and vaccines	10
2.2.3 Blood products	11
2.2.4 Essential medicines	11
2.2.5 Regulatory support	13
2.2.6 HIV-related activities	14
2.3 Counterfeit medicines	14
3. Quality control — specifications and tests	16
3.1 <i>The International Pharmacopoeia</i>	16
3.2 Current work plan and future work programme	19
3.3 Specifications for medicines, including children's medicines	23
3.3.1 Medicines for HIV and related conditions	23
3.3.2 Antimalarial medicines	23
3.3.3 Antituberculosis medicines	24
3.3.4 Other medicines	25
3.4 Revision of texts of <i>The International Pharmacopoeia</i>	26
3.4.1 Antimalarials: artemisinin derivatives	26
3.4.2 Antibiotics	27
3.4.3 Other medicines	28
3.4.4 Heparin	28
3.5 Review of published general monographs for dosage forms	29
3.6 General policy topics and general revision issues	30
3.7 Radiopharmaceuticals	33

<b>4. Quality control – international reference materials (International Chemical Reference Substances and International Infrared Reference Spectra)</b>	<b>36</b>
4.1 Annual report of the WHO Collaborating Centre	36
4.2 Adoption of new International Chemical Reference Substances	36
4.3 New institution for the establishment of international reference materials	36
<b>5. Quality control — national laboratories</b>	<b>37</b>
5.1 External Quality Assurance Assessment Scheme	37
5.2 WHO good practices for quality control laboratories	39
5.3 WHO good practices for pharmaceutical microbiology laboratories	42
<b>6. Quality assurance — good manufacturing practices</b>	<b>42</b>
6.1 WHO good manufacturing practices: main principles for pharmaceutical products	42
6.2 WHO good manufacturing practices for active pharmaceutical ingredients	43
6.3 WHO good manufacturing practices for pharmaceutical products containing hazardous substances	44
6.4 WHO good manufacturing practices for sterile pharmaceutical products	44
6.5 Updates of other WHO good manufacturing practices texts	45
6.6 Good manufacturing practices for blood establishments	45
<b>7. Quality assurance — new approaches</b>	<b>47</b>
7.1 Risk analysis	47
7.2 WHO guidelines on technology transfer	48
<b>8. Quality assurance — distribution and trade of pharmaceuticals</b>	<b>49</b>
8.1 WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce	49
8.2 WHO good distribution practices for pharmaceutical products	50
8.3 Regulatory oversight on pharmaceutical cold chain management	51
<b>9. Prequalification of priority essential medicines</b>	<b>52</b>
9.1 Prequalification Programme managed by WHO	52
9.2 Guidelines on requalification of prequalified dossiers	57
9.3 Guidelines for the preparation of a contract research organization master file	58
<b>10. Nomenclature, terminology and databases</b>	<b>59</b>
10.1 Quality assurance terminology	59
10.2 International nonproprietary names	61
10.3 Pharmacopoeial references	61
<b>11. Miscellaneous</b>	<b>62</b>
11.1 WHO Model List of Essential Medicines	62
11.2 Update on stability	62
11.3 Diethylene glycol	64
<b>12. Summary and recommendations</b>	<b>65</b>

Annex 1	
WHO good practices for pharmaceutical quality control laboratories	81
Annex 2	
WHO good manufacturing practices for active pharmaceutical ingredients	130
Annex 3	
WHO good manufacturing practices for pharmaceutical products containing hazardous substances	192
Annex 4	
WHO good manufacturing practices for sterile pharmaceutical products	209
Annex 5	
WHO good distribution practices for pharmaceutical products	235
Annex 6	
Guidelines on the requalification of prequalified dossiers	265
Annex 7	
Guidelines for the preparation of a contract research organization master file	271

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28989](https://www.yunbaogao.cn/report/index/report?reportId=5_28989)

